| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
CureVac N.V.$4.66
+0.09 (+1.97%)
D 26Pipeline Score Richly Valued Biotech · Clinical
Market Cap
1.05 B
EPS
0.72
P/E Ratio
6.52 $
Value Trade
5.32 M
8.62 %
Week
-8.98 %
1 Month
-13.86 %
3 Month
-14.18 %
6 Month
-94.52 %
5 Year
-89.41 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
1.15 M
52 Week Range
2.48 - 5.72
% held by Insiders
57.58 %
% held by Institutions
3.57 %
Enterprise Value
601.64 M
Total Shares
224.38 M
Short %
0.18 %
Float Shares
224.38 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D26
Pipeline Score $46M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 27%
Micro Cap (rank 675 of 923)
Percentile RankCureVac N.V. faces pipeline headwinds (26/100), with $526M risk-adjusted pipeline value, led by Durvalumab in Metastatic Non-small Cell Lung Cancer (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Durvalumab Small molecule | Metastatic Non-small Cell Lung Cancer | Phase 1 | NCT03164772 | 10% | $526M | COMPLETED | 61 | - | - | Oct 29, 2021 | - | Oct 10, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
seasonal influenza mRNA vaccine | seasonal influenza | Phase 2 | 2024-09-12 | positive immune responses to A and B strains, meeting all predefined success criteria in the tested age groups of older and younger adults Read More | CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, Read More | |
seasonal influenza mRNA vaccine | seasonal influenza | Phase 2 | 2024-09-12 | positive immune responses to A and B strains, meeting all predefined success criteria in the tested age groups of older and younger adults Read More | CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, Read More | |
seasonal influenza mRNA vaccine | seasonal influenza | Phase 2 | 2024-09-12 | positive immune responses to A and B strains, meeting all predefined success criteria in the tested age groups of older and younger adults Read More | CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CVAC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CVAC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How CVAC ranks across every disease it competes inCompetitive Position is a premium feature
See how CVAC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial